Brief: Vir Biotechnology Inc On Feb 21, Co And Glaxo Wellcome Uk Limited Entered Into A Letter Agreement
22/02/2024 23:27
Feb 22 (Reuters) - Vir Biotechnology Inc VIR.O :
* VIR BIOTECHNOLOGY INC: ON FEB 21, CO AND GLAXO WELLCOME UK
LIMITED ENTERED INTO A LETTER AGREEMENT
* VIR BIOTECHNOLOGY: UNDER LETTER AGREEMENT, PARTIES
MUTUALLY
AGREED TO TERMINATE COLLABORATION ON INFLUENZA PROGRAM UNDER
AGREEMENT DATED MAY 18, 2021
Source text for Eikon: ID:n0001628280-24-006346
Further company coverage: VIR.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO